{"DataElement":{"publicId":"5709523","version":"1","preferredName":"Prior Biological Therapy Administered Type","preferredDefinition":"The type of biologic therapy was used before the current study.","longName":"PRIR_BIOL_THERA_TYP","context":"DCP","contextVersion":"1","DataElementConcept":{"publicId":"2190855","version":"1","preferredName":"Prior Biological Therapy Administered","preferredDefinition":"information related to biological therapy administered previously.","longName":"PRIOR_BIOTX_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206751","version":"1","preferredName":"Prior Biological Therapy","preferredDefinition":"Earlier in time or order.:Treatment of disease by the administration of substances which produce a biological reaction in the organism. It includes the use of sera, antitoxins, vaccines, cells, tissues, and organs. (From Dorland, 28th ed)","longName":"C25629:C0005527","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Biological Therapy","conceptCode":"C0005527","definition":"Treatment of disease by the administration of substances which produce a biological reaction in the organism. It includes the use of sera, antitoxins, vaccines, cells, tissues, and organs. (From Dorland, 28th ed)","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-0309-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177665","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"Administered","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-516D-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7D7251C-548A-5E2C-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-11-02","endDate":null,"createdBy":"PWEST","dateCreated":"2004-11-02","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5709517","version":"1","preferredName":"Biologic Therapeutic Procedure Type","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Something distinguishable as an identifiable class based on common qualities.","longName":"5709517v1.0","context":"DCP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4AA01C0C-6C8D-2061-E053-F662850A2D37","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"ONEDATA","dateModified":"2017-03-13","deletedIndicator":"No"},{"value":"None","valueDescription":"None","ValueMeaning":{"publicId":"2577064","version":"1","preferredName":"None","longName":"2577064","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA15-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4AA01C0C-6C83-2061-E053-F662850A2D37","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"ONEDATA","dateModified":"2017-03-13","deletedIndicator":"No"},{"value":"Xgeva","valueDescription":"Denosumab","ValueMeaning":{"publicId":"3241060","version":"1","preferredName":"Denosumab","longName":"3241060","preferredDefinition":"A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity. Denosumab specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces, resulting in inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Denosumab","conceptCode":"C61313","definition":"A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity. Denosumab specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces, resulting in inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A443510D-A108-C5AF-E040-BB89AD435D96","latestVersionIndicator":"Yes","beginDate":"2011-05-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4AA01C0C-6CA1-2061-E053-F662850A2D37","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"ONEDATA","dateModified":"2017-03-13","deletedIndicator":"No"},{"value":"Herceptin","valueDescription":"Herceptin/Paclitaxel","ValueMeaning":{"publicId":"5709519","version":"1","preferredName":"Herceptin/Paclitaxel","longName":"5709519","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Herceptin/Paclitaxel","conceptCode":"C9759","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AA01C0C-6CAE-2061-E053-F662850A2D37","latestVersionIndicator":"Yes","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4AA01C0C-6CC7-2061-E053-F662850A2D37","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"ONEDATA","dateModified":"2017-03-13","deletedIndicator":"No"},{"value":"TDM 1","valueDescription":"Trastuzumab Emtansine","ValueMeaning":{"publicId":"4255113","version":"1","preferredName":"Trastuzumab Emtansine","longName":"4255113","preferredDefinition":"An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trastuzumab Emtansine","conceptCode":"C82492","definition":"An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5AA2DE6-BE47-4E55-E040-BB89AD43059A","latestVersionIndicator":"Yes","beginDate":"2014-03-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4AA01C0C-6CDB-2061-E053-F662850A2D37","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"ONEDATA","dateModified":"2017-03-13","deletedIndicator":"No"},{"value":"Pertuzumab","valueDescription":"Pertuzumab","ValueMeaning":{"publicId":"3378887","version":"1","preferredName":"Pertuzumab","longName":"3378887","preferredDefinition":"A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pertuzumab","conceptCode":"C38692","definition":"A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-405F-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4AA01C0C-6CE5-2061-E053-F662850A2D37","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"ONEDATA","dateModified":"2017-03-13","deletedIndicator":"No"},{"value":"Tykerb","valueDescription":"Lapatinib Ditosylate","ValueMeaning":{"publicId":"5709520","version":"1","preferredName":"Lapatinib Ditosylate","longName":"5709520","preferredDefinition":"The ditosylate salt of lapatinib, a synthetic, orally-active quinazoline with potential antineoplastic activity. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lapatinib Ditosylate","conceptCode":"C66878","definition":"The ditosylate salt of lapatinib, a synthetic, orally-active quinazoline with potential antineoplastic activity. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AA01C0C-6CEF-2061-E053-F662850A2D37","latestVersionIndicator":"Yes","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4AA01C0C-6D08-2061-E053-F662850A2D37","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"ONEDATA","dateModified":"2017-03-13","deletedIndicator":"No"},{"value":"Tarceva","valueDescription":"Erlotinib Hydrochloride","ValueMeaning":{"publicId":"5709521","version":"1","preferredName":"Erlotinib Hydrochloride","longName":"5709521","preferredDefinition":"The hydrochloride salt of a quinazoline derivative with antineoplastic properties.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Erlotinib Hydrochloride","conceptCode":"C2693","definition":"The hydrochloride salt of a quinazoline derivative with antineoplastic properties.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AA01C0C-6D12-2061-E053-F662850A2D37","latestVersionIndicator":"Yes","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4AA01C0C-6D2B-2061-E053-F662850A2D37","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"ONEDATA","dateModified":"2017-03-13","deletedIndicator":"No"},{"value":"Avastin","valueDescription":"Bevacizumab","ValueMeaning":{"publicId":"4916311","version":"1","preferredName":"Bevacizumab","longName":"4916311","preferredDefinition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bevacizumab","conceptCode":"C2039","definition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B693509-9093-B947-E050-BB89AD43520F","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ZHANGWE","dateModified":"2021-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4AA01C0C-6D3F-2061-E053-F662850A2D37","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"ONEDATA","dateModified":"2017-03-13","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2749690","version":"1","preferredName":"Therapeutic Procedure Type","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.:Type; a subdivision of a particular kind of thing.","longName":"C49236:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D35F706-1F30-4E8C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-05-14","endDate":null,"createdBy":"STURGILLJ","dateCreated":"2008-05-14","modifiedBy":"ONEDATA","dateModified":"2008-05-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AA01C0C-6C6E-2061-E053-F662850A2D37","latestVersionIndicator":"Yes","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"MAESKEB","dateModified":"2017-10-11","changeDescription":"3/13/2017 created for DCP SVAR","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3896529","version":"1","longName":"Consortia 2012 Studies","context":"DCP","ClassificationSchemeItems":[{"publicId":"5280818","version":"1","longName":"UWI2014-03-01","context":"DCP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Prior Biologic Therapy","type":"Preferred Question Text","description":"Prior Biologic Therapy","url":null,"context":"DCP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AA047D2-6905-204F-E053-F662850A2B97","latestVersionIndicator":"Yes","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"LISU","dateModified":"2020-06-07","changeDescription":"3/13/2017 created for DCP SVAR, wz.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}